Yesterday afternoon medical device maker Varian Medical Systems Inc. (VAR:NYSE) announced fourth quarter and full year unaudited earnings for the period ending September 27, 2019. The company further advised in the report of the appointment of a new president of Interventional Oncology Solutions and a new Chief Financial Officer both from within the company.
During Q4/19 the firm reported that total company revenues grew by 10% to $879 million compared to Q4/18. During the same period, GAAP operating earnings declined 3% and Non-GAAP operating earnings grew by 13%. The firm stated that Q4/19 GAAP and Non-GAAP net earnings per diluted share were $0.97 and $1.21 respectively. The company noted that "tariff exclusions had a $21 million benefit to revenues, a $4 million benefit to cost of revenues and a $2 million expense triggered by receiving the exclusion, with a net benefit to Non-GAAP operating earnings of $23 million."
For full-year 2019, total company revenues grew 10% to $3.2 billion. The company advised that GAAP operating earnings declined 7% and Non-GAAP operating earnings grew 6%. The firm indicated that FY/19 GAAP and Non-GAAP net earnings per diluted share were $3.38 and $4.63 respectively.
The company announced that effective December 1, 2019, Gary E. Bischoping, Jr., currently SVP, Finance & CFO, will take on a new role as President of Interventional Oncology Solutions. Additionally, J. Michael Bruff, currently SVP Finance and Investor Relations, will succeed Bischoping as SVP, Finance & CFO.
Varian's CEO Dow Wilson commented, "This is the second consecutive fiscal year we have reported double-digit revenue growth and 9% Oncology orders growth; our core business is strong and being powered by our continuous innovation cycle, and our acquisitions are delivering on growth expectations. . .While we have more work to do in sharpening our execution, our order and revenue growth has us looking forward to the next fiscal year. We have strong momentum exiting our fourth quarter and our long-term growth and value creation strategy is delivering for patients, clinicians and our shareholders."
The company also provided full-year 2020 guidance in the report. The firm estimates that, for FY/20, revenues will increase by 9 to 12% to a range of $3.515 to $3.612 billion. For FY/20 the company estimates Non-GAAP net earnings per diluted share of $5.30 to $5.45.
Varian Medical Systems is headquartered in Palo Alto, Calif., and employees 9,200 in 70 countries. The firm is a developer and manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, cardiac radioablation, radiosurgery, proton therapy and brachytherapy. The company claims that it harnesses advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to patient care.
Varian has a market capitalization of about $10.7 billion with approximately 91 million shares outstanding. VAR shares opened higher today at $128.91 (+$11.51, +9.80%) over yesterday's $117.40 closing price. The stock has traded between $124.54 to $135.46 per share today and currently is trading at $126.88 (+9.48, +8.07%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
